<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799027</url>
  </required_header>
  <id_info>
    <org_study_id>2022-NHLHCRF-LX-01-0201-05</org_study_id>
    <nct_id>NCT05799027</nct_id>
  </id_info>
  <brief_title>Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer</brief_title>
  <official_title>Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate raman spectroscopic analysis of bronchoscopic&#xD;
      biopsy for diagnosing lung cancer in visible lesions in the airway. The main question it aims&#xD;
      to answer are: the diagnostic efficacy raman spectroscopic analysis of bronchoscopic biopsy&#xD;
      for diagnosing lung cancer.&#xD;
&#xD;
      The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo&#xD;
      raman spectrum analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the sensitivities and specificities of Raman spectroscopic analysis of bronchoscopic biopsy for lung cancer.</measure>
    <time_frame>7 days after the biopsy</time_frame>
    <description>The diagnosis would be confirmed according to the pathological results.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Raman spectrum analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Raman spectrum</intervention_name>
    <description>The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.</description>
    <arm_group_label>Raman spectrum analysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who plan to undergo bronchoscopic biopsy or EBUS-TBNA&#xD;
&#xD;
          -  Visible intratracheal lesions under bronchoscope&#xD;
&#xD;
          -  Non-visible lesions suspected of lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient could not tolerate further examination aimed at clarifying the cause of&#xD;
             the disease or refused to accept further examination aimed at clarifying the cause of&#xD;
             the disease due to poor general condition, serious organ dysfunction, etc&#xD;
&#xD;
          -  The patient has no definite diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingming Deng, MD</last_name>
    <phone>86 18801336854</phone>
    <email>isdeng1017@163.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Gang Hou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

